A Leading Health Diagnostics Company
Dedicated to Improving the Lives of Women and Babies
Through Individualized Prenatal Care
The Pregnancy Company
Preterm birth impacts over 1 in 10 U.S. pregnancies.1
Accurately identifying women at higher risk for spontaneous preterm birth is a critical first step to addressing an early delivery’s health and economic impacts. The PreTRM® Test predicts a patient’s individual risk of spontaneous preterm delivery in asymptomatic singleton pregnancies through a single blood draw performed during weeks 19 or 20 gestational age.
News and Press Releases
Dec. 2, 2021, Sera Prognostics announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.
Dec. 1, 2021, The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.
Nov. 30, 2021, Sera Prognostics announced that Sandra A. J. Lawrence has joined the Sera Board of Directors.
Make a Difference in the Health of Moms and Babies
By working together, we can innovate with bold ideas to give babies the best start in life. Our team is passionate about becoming the global leader in high-value women’s health diagnostics. We are dedicated to improving the lives of women and babies through precision pregnancy care.
- Hamilton BE, et al. Births: Provisional data for 2020. Vital Statistics Rapid Release; no 12. Hyattsville, MD: National Center for Health Statistics. May 2021.